Extracellular Myocardial Volume in Patients With Aortic Stenosis.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
28 01 2020
Historique:
received: 03 10 2019
revised: 31 10 2019
accepted: 04 11 2019
entrez: 25 1 2020
pubmed: 25 1 2020
medline: 13 8 2020
Statut: ppublish

Résumé

Myocardial fibrosis is a key mechanism of left ventricular decompensation in aortic stenosis and can be quantified using cardiovascular magnetic resonance (CMR) measures such as extracellular volume fraction (ECV%). Outcomes following aortic valve intervention may be linked to the presence and extent of myocardial fibrosis. This study sought to determine associations between ECV% and markers of left ventricular decompensation and post-intervention clinical outcomes. Patients with severe aortic stenosis underwent CMR, including ECV% quantification using modified Look-Locker inversion recovery-based T1 mapping and late gadolinium enhancement before aortic valve intervention. A central core laboratory quantified CMR parameters. Four-hundred forty patients (age 70 ± 10 years, 59% male) from 10 international centers underwent CMR a median of 15 days (IQR: 4 to 58 days) before aortic valve intervention. ECV% did not vary by scanner manufacturer, magnetic field strength, or T1 mapping sequence (all p > 0.20). ECV% correlated with markers of left ventricular decompensation including left ventricular mass, left atrial volume, New York Heart Association functional class III/IV, late gadolinium enhancement, and lower left ventricular ejection fraction (p < 0.05 for all), the latter 2 associations being independent of all other clinical variables (p = 0.035 and p < 0.001). After a median of 3.8 years (IQR: 2.8 to 4.6 years) of follow-up, 52 patients had died, 14 from adjudicated cardiovascular causes. A progressive increase in all-cause mortality was seen across tertiles of ECV% (17.3, 31.6, and 52.7 deaths per 1,000 patient-years; log-rank test; p = 0.009). Not only was ECV% associated with cardiovascular mortality (p = 0.003), but it was also independently associated with all-cause mortality following adjustment for age, sex, ejection fraction, and late gadolinium enhancement (hazard ratio per percent increase in ECV%: 1.10; 95% confidence interval [1.02 to 1.19]; p = 0.013). In patients with severe aortic stenosis scheduled for aortic valve intervention, an increased ECV% is a measure of left ventricular decompensation and a powerful independent predictor of mortality.

Sections du résumé

BACKGROUND
Myocardial fibrosis is a key mechanism of left ventricular decompensation in aortic stenosis and can be quantified using cardiovascular magnetic resonance (CMR) measures such as extracellular volume fraction (ECV%). Outcomes following aortic valve intervention may be linked to the presence and extent of myocardial fibrosis.
OBJECTIVES
This study sought to determine associations between ECV% and markers of left ventricular decompensation and post-intervention clinical outcomes.
METHODS
Patients with severe aortic stenosis underwent CMR, including ECV% quantification using modified Look-Locker inversion recovery-based T1 mapping and late gadolinium enhancement before aortic valve intervention. A central core laboratory quantified CMR parameters.
RESULTS
Four-hundred forty patients (age 70 ± 10 years, 59% male) from 10 international centers underwent CMR a median of 15 days (IQR: 4 to 58 days) before aortic valve intervention. ECV% did not vary by scanner manufacturer, magnetic field strength, or T1 mapping sequence (all p > 0.20). ECV% correlated with markers of left ventricular decompensation including left ventricular mass, left atrial volume, New York Heart Association functional class III/IV, late gadolinium enhancement, and lower left ventricular ejection fraction (p < 0.05 for all), the latter 2 associations being independent of all other clinical variables (p = 0.035 and p < 0.001). After a median of 3.8 years (IQR: 2.8 to 4.6 years) of follow-up, 52 patients had died, 14 from adjudicated cardiovascular causes. A progressive increase in all-cause mortality was seen across tertiles of ECV% (17.3, 31.6, and 52.7 deaths per 1,000 patient-years; log-rank test; p = 0.009). Not only was ECV% associated with cardiovascular mortality (p = 0.003), but it was also independently associated with all-cause mortality following adjustment for age, sex, ejection fraction, and late gadolinium enhancement (hazard ratio per percent increase in ECV%: 1.10; 95% confidence interval [1.02 to 1.19]; p = 0.013).
CONCLUSIONS
In patients with severe aortic stenosis scheduled for aortic valve intervention, an increased ECV% is a measure of left ventricular decompensation and a powerful independent predictor of mortality.

Identifiants

pubmed: 31976869
pii: S0735-1097(19)38514-6
doi: 10.1016/j.jacc.2019.11.032
pmc: PMC6985897
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

304-316

Subventions

Organisme : British Heart Foundation
ID : FS/19/35/34374
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/14/78/31020
Pays : United Kingdom
Organisme : Department of Health
ID : PDF-2011-04-051
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/18/5/34216
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/10/32375
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/16/47/32190
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT103782AIA
Pays : United Kingdom
Organisme : Department of Health
ID : CDF 2014-07-045
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701127
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : CIHR
ID : FDN 143225
Pays : Canada
Organisme : CIHR
ID : MOP-114997
Pays : Canada
Organisme : British Heart Foundation
ID : CH/09/002
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Circ J. 2016 Apr 25;80(5):1202-9
pubmed: 26984717
J Cardiovasc Magn Reson. 2013 Oct 14;15:92
pubmed: 24124732
Eur Heart J Cardiovasc Imaging. 2018 Jun 1;19(6):615-621
pubmed: 29617988
Circulation. 1989 Apr;79(4):744-55
pubmed: 2522356
J Am Coll Cardiol. 2012 Nov 6;60(19):1854-63
pubmed: 23062541
Circ Cardiovasc Imaging. 2013 Nov;6(6):1009-17
pubmed: 24100045
J Am Coll Cardiol. 2014 Jun 10;63(22):e57-185
pubmed: 24603191
Heart. 2013 Jul;99(13):932-7
pubmed: 23349348
J Cardiovasc Magn Reson. 2015 Jun 11;17:48
pubmed: 26062931
Circ Cardiovasc Imaging. 2013 May 1;6(3):373-83
pubmed: 23553570
Circ J. 2018 Feb 23;82(3):874-885
pubmed: 29081473
J Cardiovasc Magn Reson. 2009 Mar 03;11:5
pubmed: 19257889
J Cardiovasc Magn Reson. 2016 Sep 22;18(1):58
pubmed: 27660042
Circulation. 2003 Feb 25;107(7):984-91
pubmed: 12600911
J Cardiovasc Magn Reson. 2012 Dec 28;14:88
pubmed: 23272651
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
J Cardiovasc Magn Reson. 2013 May 01;15:35
pubmed: 23634753
JACC Cardiovasc Imaging. 2017 Nov;10(11):1320-1333
pubmed: 28017384
J Cardiovasc Magn Reson. 2013 Sep 11;15:78
pubmed: 24025486
J Cardiovasc Magn Reson. 2015 Apr 18;17:29
pubmed: 25928314
JACC Cardiovasc Imaging. 2013 Sep;6(9):955-62
pubmed: 23582361
Eur Heart J. 2018 Feb 21;39(8):699-709
pubmed: 29020257
J Am Coll Cardiol. 2012 Oct 2;60(14):1259-67
pubmed: 22657269
J Cardiovasc Magn Reson. 2012 May 01;14:27
pubmed: 22548832
JACC Cardiovasc Imaging. 2018 Jul;11(7):974-983
pubmed: 29153562
J Am Soc Echocardiogr. 2017 Apr;30(4):372-392
pubmed: 28385280
Circulation. 2010 Jul 13;122(2):138-44
pubmed: 20585010
Heart. 2019 Dec;105(23):1818-1824
pubmed: 31467152
Radiology. 2015 Feb;274(2):359-69
pubmed: 25251584
J Am Coll Cardiol. 2018 Feb 27;71(8):860-871
pubmed: 29471937
Magn Reson Med. 2004 Jul;52(1):141-6
pubmed: 15236377
Circ Cardiovasc Imaging. 2018 Jun;11(6):e007451
pubmed: 29914867
J Cardiovasc Magn Reson. 2014 Oct 21;16:69
pubmed: 25384607

Auteurs

Russell J Everett (RJ)

Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: Russell.everett@ed.ac.uk.

Thomas A Treibel (TA)

Barts Health NHS Trust and University College London, London, United Kingdom.

Miho Fukui (M)

UPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, Pennsylvania.

Heesun Lee (H)

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.

Marzia Rigolli (M)

University of Oxford Centre for Clinical Magnetic Resonance Research, BHF Centre of Research Excellence (Oxford), NIHR Biomedical Research Centre (Oxford), Oxford, United Kingdom.

Anvesha Singh (A)

Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.

Petra Bijsterveld (P)

Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical Imaging, Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Lionel Tastet (L)

Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart and Lung Institute, Université Laval, Québec City, Québec, Canada.

Tarique Al Musa (TA)

Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical Imaging, Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Laura Dobson (L)

Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical Imaging, Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Calvin Chin (C)

National Heart Center Singapore, Singapore.

Gabriella Captur (G)

Inherited Heart Muscle Disease Clinic, Department of Cardiology, Royal Free Hospital, NHS Foundation Trust, London, United Kingdom.

Sang Yong Om (SY)

Division of Cardiology, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Stephanie Wiesemann (S)

Charité Campus Buch ECRC, Berlin, and Helios Clinics Cardiology Germany, DZHK partner site, Berlin, Germany.

Vanessa M Ferreira (VM)

University of Oxford Centre for Clinical Magnetic Resonance Research, BHF Centre of Research Excellence (Oxford), NIHR Biomedical Research Centre (Oxford), Oxford, United Kingdom.

Stefan K Piechnik (SK)

University of Oxford Centre for Clinical Magnetic Resonance Research, BHF Centre of Research Excellence (Oxford), NIHR Biomedical Research Centre (Oxford), Oxford, United Kingdom.

Jeanette Schulz-Menger (J)

Charité Campus Buch ECRC, Berlin, and Helios Clinics Cardiology Germany, DZHK partner site, Berlin, Germany.

Erik B Schelbert (EB)

UPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, Pennsylvania.

Marie-Annick Clavel (MA)

Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart and Lung Institute, Université Laval, Québec City, Québec, Canada.

David E Newby (DE)

Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, United Kingdom.

Saul G Myerson (SG)

University of Oxford Centre for Clinical Magnetic Resonance Research, BHF Centre of Research Excellence (Oxford), NIHR Biomedical Research Centre (Oxford), Oxford, United Kingdom.

Phillipe Pibarot (P)

Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart and Lung Institute, Université Laval, Québec City, Québec, Canada.

Sahmin Lee (S)

Division of Cardiology, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.

João L Cavalcante (JL)

UPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, Pennsylvania.

Seung-Pyo Lee (SP)

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.

Gerry P McCann (GP)

Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.

John P Greenwood (JP)

Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical Imaging, Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

James C Moon (JC)

Barts Health NHS Trust and University College London, London, United Kingdom.

Marc R Dweck (MR)

Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH